Cencora (NYSE:COR – Get Free Report) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $13.55-$13.65 for the period, compared to the consensus earnings per share estimate of $13.47. The company issued revenue guidance of $293.6 billion, compared to the consensus revenue estimate of $289.77 billion. Cencora also updated its FY 2024 guidance to 13.550-13.650 EPS.
Cencora Stock Up 1.3 %
Shares of NYSE:COR traded up $3.11 during midday trading on Friday, reaching $247.57. 3,292,432 shares of the company were exchanged, compared to its average volume of 1,217,035. Cencora has a fifty-two week low of $171.65 and a fifty-two week high of $247.66. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. The stock has a fifty day simple moving average of $228.85 and a two-hundred day simple moving average of $231.18. The firm has a market cap of $49.38 billion, a PE ratio of 27.09, a P/E/G ratio of 1.68 and a beta of 0.45.
Cencora (NYSE:COR – Get Free Report) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 EPS for the quarter, topping analysts’ consensus estimates of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same period last year, the business posted $2.92 earnings per share. The firm’s quarterly revenue was up 10.8% on a year-over-year basis. As a group, sell-side analysts forecast that Cencora will post 13.56 earnings per share for the current year.
Cencora Dividend Announcement
Analysts Set New Price Targets
COR has been the topic of several recent research reports. Wells Fargo & Company lifted their price target on shares of Cencora from $236.00 to $249.00 and gave the company an equal weight rating in a research note on Thursday. StockNews.com raised shares of Cencora from a buy rating to a strong-buy rating in a research report on Friday. Citigroup lifted their price objective on shares of Cencora from $265.00 to $280.00 and gave the company a buy rating in a research report on Tuesday, April 30th. SVB Leerink reissued an outperform rating and issued a $275.00 price objective on shares of Cencora in a research report on Thursday, June 27th. Finally, Robert W. Baird lifted their price objective on shares of Cencora from $285.00 to $287.00 and gave the company an outperform rating in a research report on Thursday. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus target price of $243.00.
Read Our Latest Research Report on Cencora
Insiders Place Their Bets
In other Cencora news, Director Dermot Mark Durcan acquired 500 shares of the company’s stock in a transaction on Friday, May 24th. The stock was acquired at an average price of $218.58 per share, for a total transaction of $109,290.00. Following the purchase, the director now directly owns 21,876 shares of the company’s stock, valued at $4,781,656.08. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, CEO Steven H. Collis sold 10,755 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the completion of the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Dermot Mark Durcan acquired 500 shares of the stock in a transaction that occurred on Friday, May 24th. The shares were bought at an average price of $218.58 per share, with a total value of $109,290.00. Following the completion of the transaction, the director now owns 21,876 shares in the company, valued at $4,781,656.08. The disclosure for this purchase can be found here. Insiders sold 1,899,112 shares of company stock worth $408,654,376 in the last quarter. 15.80% of the stock is currently owned by corporate insiders.
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
- Five stocks we like better than Cencora
- What is a Death Cross in Stocks?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Investing in Travel Stocks Benefits
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Health Care Stocks Explained: Why You Might Want to Invest
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.